Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

• Published in: The lancet oncology Vol. 13; no. 5; pp. 501 - 508
• Main Authors: Madan, Ravi A, MD, Mohebtash, Mahsa, MD, Arlen, Philip M, MD, Vergati, Matteo, MD, Rauckhorst, Myrna, RN, Steinberg, Seth M, PhD, Tsang, Kwong Y, PhD, Poole, Diane J, Parnes, Howard L, MD, Wright, John J, MD PhD, Dahut, William L, MD, Schlom, Jeffrey, PhD, Gulley, James L, Dr
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-05-2012; Elsevier Limited
• Subjects: Aged; Aged, 80 and over; Antibodies, Monoclonal - therapeutic use; Antigens; Antigens, CD - immunology; Antineoplastic Agents - therapeutic use; Cancer therapies; Cancer vaccines; Cancer Vaccines - immunology; Cancer Vaccines - therapeutic use; Chemotherapy; Cytotoxicity; Dose-Response Relationship, Drug; FDA approval; Hematology, Oncology and Palliative Medicine; Humans; Immunotherapy, Active; Ipilimumab; Lymphocytes; Male; Melanoma; Metastasis; Middle Aged; Monoclonal antibodies; Orchiectomy; Poxviridae - immunology; Prostate cancer; Prostate-Specific Antigen - immunology; Prostatic Neoplasms - immunology; Prostatic Neoplasms - secondary; Prostatic Neoplasms - therapy; Viral Vaccines - immunology; Viral Vaccines - therapeutic use; United States > US
• ISSN: 1470-2045; 1474-5488
• DOI: 10.1016/S1470-2045(12)70006-2

Summary Background Therapeutic cancer vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and methods are being assessed to enhance their efficacy. Ipilimumab is an antagonistic monoclonal antibody that binds cytotoxic T-lymphocyte-associated protein 4, an immunomodulatory molecule expressed by activated T cells, and to CD80 on antigen-presenting cells. We aimed to assess the safety and tolerability of ipilimumab in combination with a poxviral-based vaccine targeting prostate-specific antigen (PSA) and containing transgenes for T-cell co-stimulatory molecule expression, including CD80. Methods We did a phase 1 dose-escalation trial, with a subsequent expansion phase, to assess the safety and tolerability of escalating doses of ipilimumab in combination with a fixed dose of the PSA-Tricom vaccine. Patients with mCRPC received 2×108 plaque-forming units of recombinant vaccinia PSA-Tricom subcutaneously on day 1 of cycle 1, with subsequent monthly boosts of 1×109 plaque-forming units, starting on day 15. Intravenous ipilimumab was given monthly starting at day 15, in doses of 1, 3, 5, and 10 mg/kg. Our primary goal was to assess the safety of the combination. This study is registered with ClinicalTrials.gov , number NCT00113984. Findings We completed enrolment with 30 patients (24 of whom had not been previously treated with chemotherapy) and we did not identify any dose-limiting toxic effects. Grade 1 and 2 vaccination-site reactions were the most common toxic effects: three of 30 patients had grade 1 reactions and 26 had grade 2 reactions. 21 patients had grade 2 or greater immune-related adverse events. Grade 3 or 4 immune-related adverse events included diarrhoea or colitis in four patients and grade 3 rash (two patients), grade 3 raised aminotransferases (two patients), grade 3 endocrine immune-related adverse events (two patients), and grade 4 neutropenia (one patient). Only one of the six patients previously treated with chemotherapy had a PSA decline from baseline. Of the 24 patients who were chemotherapy-naive, 14 (58%) had PSA declines from baseline, of which six were greater than 50%. Interpretation The use of a vaccine targeting PSA that also enhances co-stimulation of the immune system did not seem to exacerbate the immune-related adverse events associated with ipilimumab. Randomised trials are needed to further assess clinical outcomes of the combination of ipilimumab and vaccine in mCRPC. Funding US National Institutes of Health.